Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FGFR2 Gene Rearrangements”

12 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 12 results

Not applicableApproved For MarketingNCT04507503
What this trial is testing

Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Who this might be right for
Advanced Cholangiocarcinoma
Taiho Oncology, Inc.
Large-scale testing (Phase 3)Not Yet RecruitingNCT07328919
What this trial is testing

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

Who this might be right for
Intrahepatic Cholangiocarcinoma (Icc)Advanced Cholangiocarcinoma
TransThera Sciences (Nanjing), Inc. 138
Testing effectiveness (Phase 2)Study completedNCT03230318
What this trial is testing

Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Who this might be right for
Intrahepatic CholangiocarcinomaCombined Hepatocellular and Cholangiocarcinoma
Basilea Pharmaceutica 148
Large-scale testing (Phase 3)Ended earlyNCT04093362
What this trial is testing

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Who this might be right for
Advanced CholangiocarcinomaFGFR2 Gene Rearrangements
Taiho Oncology, Inc. 10
Testing effectiveness (Phase 2)Ended earlyNCT05565794
What this trial is testing

Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements

Who this might be right for
Intrahepatic CholangiocarcinomaFGFR2 Gene MutationFGFR2 Gene Rearrangement+1 more
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 2
Testing effectiveness (Phase 2)WithdrawnNCT05222165
What this trial is testing

Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

Who this might be right for
Advanced Solid TumorCNS TumorRecurrent WHO Grade II Glioma
Helsinn Healthcare SA
Not applicableUnknownNCT04921553
What this trial is testing

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)

Who this might be right for
CancerCancer MetastaticNTRK Gene Fusion Overexpression+13 more
Centre Leon Berard 500
Testing effectiveness (Phase 2)Looking for participantsNCT05727176
What this trial is testing

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Who this might be right for
Advanced CholangiocarcinomaFGFR2 FusionsGene Rearrangement
Taiho Oncology, Inc. 120
Testing effectiveness (Phase 2)Looking for participantsNCT06728410
What this trial is testing

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Who this might be right for
Intrahepatic CholangiocarcinomaFGFR2 Gene RearrangementFGFR2 Gene Mutation
Mehmet Akce 38
Testing effectiveness (Phase 2)Looking for participantsNCT05678270
What this trial is testing

ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Who this might be right for
Intrahepatic Cholangiocarcinoma (ICC)
Beijing InnoCare Pharma Tech Co., Ltd. 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT05174650
What this trial is testing

Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

Who this might be right for
Intrahepatic Cholangiocarcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 27
Testing effectiveness (Phase 2)Looking for participantsNCT07786766
What this trial is testing

Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma

Who this might be right for
Biliary Tract Cancer (BTC)
Haitao Zhao, MD 154